Germany Asthma Biologics Market Insight
Published: 11 June 2026 | Report Format: Electronic (PDF)
market for asthma biologics in Germany is expected to increase at compound annual growth rate (CAGR) of 5.84% because to rising prevalence of severe asthma, growing demand for healthcare infrastructure.
Germany Asthma Biologics Market Insights Forecasts to 2035
- The Germany Asthma Biologics Market Size Was Estimated USD 760.3 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.81% from 2025 to 2035
- The Germany Asthma Biologics Market Size is Expected to rise around USD 1100.1 Million by 2035
Notable Insights for the Germany Asthma Biologics Market
- Based on mechanism of action segmentation, the German asthma biologics market is dominated by anti-IL-5/IL-5Rα; anti-IgE and anti-IL-4Rα are growing steadily, and anti-TSLP is becoming more popular in advanced severe asthma treatment applications.
- Based on patient phenotype segmentation, Germany is dominated by eosinophilic asthma. asthma biologics market, Personalized biologic therapies and an increase in severe asthma cases are driving the steady growth of the allergic/IgE-mediated and OCS-dependent asthma segments.
- Biologics like Dupixent, Xolair, and Fasenra are reimbursed up to 100% for qualified severe asthma patients under Germany's SHI system, which covers over 88% of the population, increasing adoption rates.
- About 13% of asthma patients in Germany have severe symptoms; more than 60% of the demand for biologics is for anti-IL-5 and anti-IL-4R treatments for eosinophilic patients who are not responding to conventional inhaled corticosteroids.
Download the eBook (ToC)
Why Buy This Report
- Learn everything there is to know about the German asthma biologics market, including a thorough examination of market size, growth projections, and major factors influencing demand for cutting-edge biologic treatments through 2035.
- Learn about the competitive stance of top biologics including Dupixent, Xolair, and Fasenra, as well as business strategies, innovations, and changing treatment environments in Germany.
- Determine high-growth segments based on treatment adoption, patient phenotype, and mode of action so that stakeholders may successfully target eosinophilic, allergic, and severe asthma populations with precision-driven therapeutic approaches.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Germany asthma biologics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Germany Asthma Biologics Market
- AstraZeneca
- Sanofi
- GlaxoSmithKline
- Novartis
- Boehringer Ingelheim
- AbbVie
- Roche
- Amgen
- Teva
- Merck
Recent Developments:
- In December 2025, introduced the first twice-yearly asthma biologic, Depemokimab (Exdensur), which is anticipated to be released in Europe in early 2026.
- In June 2025, strengthened the positioning of biologics in Europe by collaborating with Regeneron to deliver fresh clinical data demonstrating Dupixent's superiority in asthma-related outcomes.
Market Segmentation:
Germany Asthma Biologics Market, By Mechanism of Action
- Anti-IL-5 / Anti-IL-5Rα
- Anti-IL-4Rα
- Anti-TSLP
Germany Asthma Biologics Market, By Patient Phenotype
- Eosinophilic Asthma
- Allergic / IgE-Mediated Asthma
- OCS-Dependent Asthma
Germany Asthma Biologics Market, By Distribution Channel
- Hospital Pharmacies
- Specialty Clinics
- Online and Retail Pharmacies
Expert Views:
Germany asthma biologics market can experience stable growth in coming years due to increasing incidences of severe asthma, robust reimbursement systems, and growing usage of targeted biologics. Innovation in mechanism-based drugs and individualized treatment regimes will fuel innovation in the market, whereas consistent investment in the healthcare system will ensure more growth opportunities.
Author: Komal and Radhika By Spherical Insights and Consulting